Skye Bioscience, Inc.
SKYE
$1.91
$0.094.95%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | 29.43% | 50.74% | -98.55% | -73.55% | -93.23% |
| Total Depreciation and Amortization | 140.31% | 19.15% | -10.05% | -2.06% | 8.09% |
| Total Amortization of Deferred Charges | 81.57% | 641.26% | 368.16% | 69.44% | -32.60% |
| Total Other Non-Cash Items | -87.09% | -95.90% | 193.30% | 170.53% | 243.85% |
| Change in Net Operating Assets | -460.01% | 1.98% | -514.44% | 22.28% | 38.38% |
| Cash from Operations | -80.89% | -39.59% | -51.77% | -5.11% | -9.48% |
| Capital Expenditure | -12,630.95% | -1,745.27% | 49.12% | 85.28% | 86.67% |
| Sale of Property, Plant, and Equipment | -75.45% | -77.99% | -79.30% | -79.30% | -- |
| Cash Acquisitions | -- | -100.00% | -80.02% | -79.72% | -79.72% |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -103.72% | -102.80% | -79.91% | -79.45% | 26.51% |
| Total Debt Issued | -- | -100.00% | 630.46% | 630.46% | 630.46% |
| Total Debt Repaid | -- | 97.43% | 90.00% | 75.55% | 70.90% |
| Issuance of Common Stock | 667.44% | 632.16% | -- | -- | 599,900.00% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -2,273.44% | -4,318.33% | -- | -- | -- |
| Cash from Financing | 408.19% | 406.26% | 44,363.54% | 52,560.76% | 7,978.87% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 539.10% | 351.61% | 3,577.66% | 2,788.57% | 217.43% |